| Trial ID: | L6499 |
| Source ID: | NCT01782261
|
| Associated Drug: |
Liraglutide
|
| Title: |
Incretin Effect on the Immunological Phenotype
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Liraglutide|DRUG: Saxagliptin
|
| Outcome Measures: |
Primary: Increase of regulatory FOXP3+ T cells, the effects of incretin based therapy on regulatory FOXP3+ T cells will be measured at baseline and after 4 weeks, 4 weeks | Secondary: Immunophenotyping, The effect of incretin based therapy on circulating immune cells and cytokine secretion at baseline and after 4 weeks, 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: Medical University of Graz
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-02
|
| Completion Date: |
2015-02
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-11
|
| Locations: |
Medical University Graz, Graz, 8036, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT01782261
|
